MCID: MYL075
MIFTS: 49

Myelodysplastic/myeloproliferative Neoplasm

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Myelodysplastic/myeloproliferative Neoplasm

MalaCards integrated aliases for Myelodysplastic/myeloproliferative Neoplasm:

Name: Myelodysplastic/myeloproliferative Neoplasm 12 52 15 37 17
Myelodysplastic/myeloproliferative Disease 52 58
Myeloproliferative/myelodysplastic Syndromes 12
Myelodysplastic/myeloproliferative Neoplasms 36
Myelodysplastic-Myeloproliferative Diseases 43
Myelodysplastic Myeloproliferative Disease 12
Myelodysplastic Myeloproliferative Cancer 12

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:4972
KEGG 36 H02410
MeSH 43 D054437
NCIt 49 C27262
SNOMED-CT 67 397336008 445738007
ICD10 32 C94.6
MESH via Orphanet 44 D054437
UMLS via Orphanet 72 C1301355
Orphanet 58 ORPHA98275
UMLS 71 C1301355

Summaries for Myelodysplastic/myeloproliferative Neoplasm

NIH Rare Diseases : 52 Myelodysplastic/myeloproliferative diseases are a group of diseases of the blood and bone marrow in which the bone marrow makes too many white blood cells . These disease have features of both myelodysplastic syndromes and myeloproliferative disorders . In myelodysplastic diseases, the blood stem cells do not mature into healthy red blood cells , white blood cells , or platelets and as a result, there are fewer of these healthy cells. In myeloproliferative diseases, a greater than normal number of blood stem cells develop into one or more types of blood cells and the total number of blood cells slowly increases. The 3 main types of myelodysplastic/myeloproliferative diseases include chronic myelomonocytic leukemia (CMML); juvenile myelomonocytic leukemia (JMML); and atypical chronic myelogenous leukemia (aCML). When a myelodysplastic/myeloproliferative disease does not match any of these types, it is called myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). Symptoms of CMML and JMML may include fever, feeling tired and weight loss. Symptoms of aCML may include easy bruising or bleeding and feeling tired or weak. Myelodysplastic/myeloproliferative diseases may progress to acute leukemia. There are different types of treatment for individuals with one of these diseases, which may include chemotherapy , another drug therapy, stem cell transplant and/or supportive care.

MalaCards based summary : Myelodysplastic/myeloproliferative Neoplasm, also known as myelodysplastic/myeloproliferative disease, is related to atypical chronic myeloid leukemia and thrombocytosis. An important gene associated with Myelodysplastic/myeloproliferative Neoplasm is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Ras signaling pathway and Cytokine Signaling in Immune system. The drugs Mercaptopurine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A myeloid neoplasm that results in the overproduction of white blood cells.

KEGG : 36 Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are hybrid group of chronic myeloid neoplasms combining features of both myelodysplastic (MDS) [DS:H01481] and myeloproliferative neoplasms (MPN). This group includes chronic myelomonocytic leukemia (CMML), its pediatric counterpart juvenile myelomonocytic leukemia (JMML), MDS/MPN with ringed sideroblasts and thrombocytosis (MDS/MPN-RS-T), atypical BCR-ABL1 negative chronic myeloid leukemia (aCML) and MDS/MPN- unclassifiable (MDS/MPN-u). Somatic mutations observed in MDS/MPN fall in 4 major categories, including signaling, splicing, epigenetic, and transcription gene mutations.

Related Diseases for Myelodysplastic/myeloproliferative Neoplasm

Diseases related to Myelodysplastic/myeloproliferative Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
# Related Disease Score Top Affiliating Genes
1 atypical chronic myeloid leukemia 31.5 U2AF1 TET2 SRSF2 SETBP1 RARS1 LUC7L2
2 thrombocytosis 31.2 U2AF1 TET2 JAK2 CSF2 ASXL1
3 juvenile myelomonocytic leukemia 30.7 U2AF1 TET2 SETBP1 PTPN11 NRAS NF1
4 myeloid sarcoma 30.5 U2AF1 KMT2A FLT3
5 neutropenia 30.4 PTPN11 FLT3 CSF3R CSF2
6 mastocytosis 30.3 TET2 SRSF2 PTPN11 JAK2 FLT3 ASXL1
7 megakaryocytic leukemia 30.2 U2AF1 KMT2A JAK2 CSF2
8 essential thrombocythemia 30.2 U2AF1 TET2 PTPN11 JAK2 CSF2 ASXL1
9 myelofibrosis 29.7 U2AF1 TET2 SRSF2 SETBP1 JAK2 HRAS
10 systemic mastocytosis 29.6 U2AF1 TET2 SRSF2 PTPN11 NRAS JAK2
11 aplastic anemia 29.5 U2AF1 TET2 NRAS FLT3 CSF3R CSF2
12 acute promyelocytic leukemia 29.5 U2AF1 RARS1 NRAS KMT2A HRAS FLT3
13 myeloproliferative neoplasm 29.5 U2AF1 TET2 PTPN11 NRAS NF1 LUC7L2
14 polycythemia vera 29.4 U2AF1 TET2 PTPN11 JAK2 FLT3 DNMT3A
15 myeloid leukemia 29.3 U2AF1 TET2 PTPN11 NRAS KMT2A JAK2
16 leukemia, acute lymphoblastic 29.0 U2AF1 PTPN11 MIR196A1 KMT2A JAK2 HRAS
17 leukemia, chronic myeloid 28.9 U2AF1 SETBP1 PTPN11 NRAS NF1 MIR196A1
18 chronic myelomonocytic leukemia 28.8 U2AF1 TET2 SRSF2 SETBP1 PTPN11 NRAS
19 myelodysplastic syndrome 28.8 U2AF1 TET2 SRSF2 SETBP1 PTPN11 NRAS
20 leukemia 28.7 U2AF1 TET2 PTPN11 NRAS NF1 KMT2A
21 leukemia, acute myeloid 27.8 U2AF1 TET2 SRSF2 SETBP1 RARS1 PTPN11
22 unclassified myelodysplastic/myeloproliferative disease 12.6
23 refractory anemia 10.6
24 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.5 JAK2 ABL1
25 malignant anus melanoma 10.5 NRAS HRAS
26 malignant dermis tumor 10.4 NRAS HRAS
27 malignant skin fibrous histiocytoma 10.4 NRAS HRAS
28 cytogenetically normal acute myeloid leukemia 10.4 KMT2A FLT3
29 acneiform dermatitis 10.4 NRAS HRAS
30 vulvar melanoma 10.4 NRAS HRAS
31 testicular spermatocytic seminoma 10.4 PTPN11 HRAS DNMT3A
32 central nervous system melanocytic neoplasm 10.4 NRAS HRAS
33 malignant spindle cell melanoma 10.4 NRAS NF1 HRAS
34 mental retardation, autosomal dominant 29 10.4 SETBP1 ABL1
35 monoclonal gammopathy of uncertain significance 10.4 U2AF1 LUC7L2 HRAS
36 neurofibromatosis-noonan syndrome 10.4 PTPN11 NF1 HRAS
37 pulmonic stenosis 10.4 PTPN11 NF1 HRAS
38 nevus, epidermal 10.4 NRAS NF1 HRAS
39 shwachman-diamond syndrome 1 10.4 U2AF1 LUC7L2 CSF3R
40 systemic mastocytosis with associated hematologic neoplasm 10.4 TET2 SRSF2 ASXL1
41 skin granular cell tumor 10.3 PTPN11 NF1
42 costello syndrome 10.3 PTPN11 NF1 HRAS
43 leukemia, acute monocytic 10.3 U2AF1 KMT2A FLT3
44 uveal disease 10.3 U2AF1 NRAS HRAS
45 cebpa-associated familial acute myeloid leukemia 10.3 JAK2 FLT3 DNMT3A
46 acute monoblastic leukemia 10.3 NF1 KMT2A CSF2
47 ras-associated autoimmune leukoproliferative disorder 10.3 RARS1 NRAS HRAS
48 noonan syndrome with multiple lentigines 10.3 PTPN11 NF1 HRAS
49 neurofibromatosis, type i 10.3 PTPN11 NF1 HRAS
50 langerhans cell histiocytosis 10.3 U2AF1 NRAS CSF2

Graphical network of the top 20 diseases related to Myelodysplastic/myeloproliferative Neoplasm:



Diseases related to Myelodysplastic/myeloproliferative Neoplasm

Symptoms & Phenotypes for Myelodysplastic/myeloproliferative Neoplasm

GenomeRNAi Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10 HRAS
2 Decreased viability GR00055-A-2 10 HRAS
3 Decreased viability GR00173-A 10 FLT3
4 Decreased viability GR00221-A-1 10 ABL1 ETNK1 HRAS NF1 FLT3 NRAS
5 Decreased viability GR00221-A-2 10 ABL1 ETNK1 HRAS JAK2 NF1
6 Decreased viability GR00221-A-3 10 ABL1 ETNK1 HRAS NRAS
7 Decreased viability GR00221-A-4 10 ETNK1 NF1 FLT3
8 Decreased viability GR00249-S 10 NF1
9 Decreased viability GR00342-S-1 10 ABL1 ETNK1
10 Decreased viability GR00342-S-2 10 ABL1
11 Decreased viability GR00342-S-3 10 ABL1
12 Decreased viability GR00386-A-1 10 NF1

MGI Mouse Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 ABL1 ASXL1 CSF2 CSF3R DNMT3A HRAS
2 cellular MP:0005384 10.29 ABL1 ASXL1 CSF2 CSF3R DNMT3A FLT3
3 cardiovascular system MP:0005385 10.24 ABL1 CSF2 DNMT3A HRAS JAK2 KMT2A
4 endocrine/exocrine gland MP:0005379 10.21 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS
5 hematopoietic system MP:0005397 10.21 ABL1 ASXL1 CSF2 CSF3R DNMT3A ETNK1
6 growth/size/body region MP:0005378 10.18 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS
7 immune system MP:0005387 10.17 ABL1 ASXL1 CSF2 CSF3R DNMT3A ETNK1
8 craniofacial MP:0005382 10.06 ABL1 ASXL1 CSF2 HRAS KMT2A NF1
9 mortality/aging MP:0010768 10.03 ABL1 ASXL1 CSF2 CSF3R DNMT3A FLT3
10 liver/biliary system MP:0005370 9.86 ABL1 ASXL1 JAK2 KMT2A NF1 NRAS
11 neoplasm MP:0002006 9.65 ASXL1 CSF2 FLT3 HRAS JAK2 KMT2A
12 skeleton MP:0005390 9.36 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS

Drugs & Therapeutics for Myelodysplastic/myeloproliferative Neoplasm

Drugs for Myelodysplastic/myeloproliferative Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 284)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mercaptopurine Approved Phase 3 50-44-2 667490
2
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
3
leucovorin Approved Phase 3 58-05-9 6006 143
4
Daunorubicin Approved Phase 3 20830-81-3 30323
5
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
6
Thioguanine Approved Phase 3 154-42-7 2723601
7
Idarubicin Approved Phase 3 58957-92-9 42890
8
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
9
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Acyclovir Approved Phase 3 59277-89-3 2022
12
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
13
Amitriptyline Approved Phase 3 50-48-6 2160
14
Perphenazine Approved Phase 3 58-39-9 4748
15
Baclofen Approved Phase 3 1134-47-0 2284
16
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
17
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
18
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
19
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
20
Polyestradiol phosphate Approved Phase 3 28014-46-2
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
23
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
24 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
25 Vitamin B Complex Phase 3
26 Folate Phase 3
27 Folic Acid Antagonists Phase 3
28 Vitamin B9 Phase 3
29 Analgesics Phase 3
30 Analgesics, Non-Narcotic Phase 3
31 Keratolytic Agents Phase 3
32 Neurotransmitter Agents Phase 3
33 Analgesics, Opioid Phase 3
34 Psychotropic Drugs Phase 3
35 Antipsychotic Agents Phase 3
36 Cola Phase 3
37 Ophthalmic Solutions Phase 3
38 Hydrocortisone 17-butyrate 21-propionate Phase 3
39 Hydrocortisone-17-butyrate Phase 3
40 Hydrocortisone hemisuccinate Phase 3
41
asparaginase Phase 3
42 Narcotics Phase 3
43 Anesthetics Phase 3
44 Anesthetics, General Phase 3
45 Anesthetics, Intravenous Phase 3
46 valacyclovir Phase 3
47 Antidepressive Agents Phase 3
48 Liver Extracts Phase 3
49 Excitatory Amino Acid Antagonists Phase 3
50 Adrenergic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
2 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
5 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
6 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
7 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
8 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
9 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
10 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
11 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
12 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
13 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
14 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
15 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
16 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
17 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
18 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
19 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
20 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
21 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
22 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
24 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
25 Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
26 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
27 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
28 Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes Completed NCT00003961 Phase 2
29 Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes Completed NCT00052832 Phase 2
30 ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
31 Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG and Etanercept Completed NCT00217386 Phase 2
32 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
33 Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
34 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
35 Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States Completed NCT00002809 Phase 2 cyclophosphamide;methotrexate;tacrolimus
36 A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
37 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
38 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
39 A Multicenter Study of Unrelated Umbilical Cord Blood as an Alternate Source of Stem Cells for Transplantation Completed NCT00003913 Phase 2 busulfan;cyclophosphamide;methylprednisolone
40 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
41 Allogeneic Peripheral Blood Progenitor Cell Transplantation Using Histocompatible Sibling-Matched Donor Cells After High-Dose Busulfan/Cyclophosphamide as Therapy for Hematologic Malignancies Completed NCT00003116 Phase 2 busulfan;cyclophosphamide;cyclosporine
42 Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
43 Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors Completed NCT00054327 Phase 2 busulfan;cyclophosphamide;cytarabine;Etoposide
44 Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes Completed NCT00053287 Phase 2 carboplatin;fludarabine phosphate;thalidomide;topotecan hydrochloride
45 Low Dose Total-Body Irradiation And Fludarabine Followed By HLA Matched Allogeneic Stem Cell Transplantation For Hematologic Malgnancies - A Multi-Center Study Completed NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
46 A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
47 Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant Completed NCT00530218 Phase 2 Ganciclovir
48 Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial Completed NCT00068276 Phase 2
49 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
50 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus

Search NIH Clinical Center for Myelodysplastic/myeloproliferative Neoplasm

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Myelodysplastic/myeloproliferative Neoplasm:
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Embryonic/Adult Cultured Cells Related to Myelodysplastic/myeloproliferative Neoplasm:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: myelodysplastic-myeloproliferative diseases

Genetic Tests for Myelodysplastic/myeloproliferative Neoplasm

Anatomical Context for Myelodysplastic/myeloproliferative Neoplasm

MalaCards organs/tissues related to Myelodysplastic/myeloproliferative Neoplasm:

40
Myeloid, Bone, Bone Marrow, T Cells, Liver, Nk Cells, Lung

Publications for Myelodysplastic/myeloproliferative Neoplasm

Articles related to Myelodysplastic/myeloproliferative Neoplasm:

(show top 50) (show all 111)
# Title Authors PMID Year
1
RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. 61
32209330 2020
2
Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. 61
31776464 2020
3
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term? 61
32460977 2020
4
Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? 61
32460987 2020
5
Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. 61
32460983 2020
6
A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case Report and Literature Review. 61
32398637 2020
7
Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. 61
31977035 2020
8
Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. 61
31750750 2020
9
Successful prevention of severe allergic transfusion reactions with omalizumab. 61
32134497 2020
10
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. 61
31904665 2020
11
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. 61
31511613 2020
12
Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia. 61
32328464 2020
13
Myelodysplastic/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni Syndrome. 61
31230491 2019
14
Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. 61
31017498 2019
15
JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. 61
31418453 2019
16
"Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows". 61
31102331 2019
17
Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. 61
30811101 2019
18
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". 61
30618061 2019
19
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. 61
30902805 2019
20
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis. 61
30726782 2019
21
Chronic Neutrophilic Leukemia: Current and Future Perspectives. 61
30581159 2019
22
A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis 61
30468430 2019
23
Molecular Cytogenetic Characterization of a Case of a Myelodysplastic/Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia-1 (CMML-1) with Abnormal Karyotype with an Apparent Monosomy 7 Resulting in Rearrangements Involving Chromosomes 7 and 21. 61
30840601 2019
24
[Essential thrombocythemia correctly diagnosed through the guidance of comprehensive genomic profiling]. 61
31902812 2019
25
[Concurrent CALR and SF3B1 gene mutations in a patient with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis]. 61
31484889 2019
26
Gender disparity in the survival of patients with primary myelodysplastic syndrome. 61
30854142 2019
27
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. 61
31723789 2018
28
Refractoriness to red blood cell transfusion therapy due to hypersplenism. 61
30260482 2018
29
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. 61
30242087 2018
30
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. 61
29465270 2018
31
Integrated molecular profiling of juvenile myelomonocytic leukemia. 61
29437595 2018
32
Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. 61
29514790 2018
33
[Myelodysplastic/myeloproliferative neoplasm: a histopathological review]. 61
30305512 2018
34
[FGFR1-mutated B-cell acute lymphoblastic leukemia transforming to myelodysplastic / myeloproliferative neoplasm and acute myeloid leukemia]. 61
30078796 2018
35
Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic/myeloproliferative neoplasm. 61
29692658 2018
36
Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia. 61
29707521 2018
37
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. 61
28548124 2017
38
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. 61
28927137 2017
39
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. 61
28495918 2017
40
Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. 61
28442268 2017
41
Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases. 61
28059092 2017
42
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. 61
28188970 2017
43
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis with co-mutated JAK2 and SF3B1. 61
28153838 2017
44
Acute myeloid leukemia with t(3;21)(q13;q22), a novel simple variant of the 21q22/RUNX1 translocation. 61
28190862 2017
45
[Juvenile myelomonocytic leukemia: A three-case series]. 61
27789175 2016
46
Suspected myelodysplastic/myeloproliferative neoplasm in a feline leukemia virus-negative cat. 61
27870069 2016
47
Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia. 61
27240832 2016
48
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. 61
27385790 2016
49
Urgent Coronary Artery Bypass Surgery in a Patient with Postinfarction Angina and Active Myelomonocytic Leukaemia. 61
27990115 2016
50
Trim33/Tif1γ is involved in late stages of granulomonopoiesis in mice. 61
27130375 2016

Variations for Myelodysplastic/myeloproliferative Neoplasm

Expression for Myelodysplastic/myeloproliferative Neoplasm

Search GEO for disease gene expression data for Myelodysplastic/myeloproliferative Neoplasm.

Pathways for Myelodysplastic/myeloproliferative Neoplasm

Pathways related to Myelodysplastic/myeloproliferative Neoplasm according to KEGG:

36
# Name Kegg Source Accession
1 Ras signaling pathway hsa04014

Pathways related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.14 PTPN11 NRAS NF1 JAK2 HRAS FLT3
2
Show member pathways
12.68 PTPN11 NRAS HRAS FLT3 CSF2 ABL1
3 12.57 NRAS JAK2 HRAS FLT3 CSF3R ABL1
4
Show member pathways
12.46 PTPN11 NRAS JAK2 HRAS CSF2
5
Show member pathways
12.42 NRAS JAK2 HRAS ABL1
6
Show member pathways
12.4 PTPN11 NRAS JAK2 HRAS
7
Show member pathways
12.32 PTPN11 NF1 JAK2 HRAS
8
Show member pathways
12.3 PTPN11 NRAS HRAS FLT3
9
Show member pathways
12.28 PTPN11 NRAS NF1 HRAS FLT3 ABL1
10
Show member pathways
12.25 NRAS JAK2 HRAS FLT3
11
Show member pathways
12.2 NRAS NF1 JAK2 HRAS
12
Show member pathways
12.19 PTPN11 NRAS JAK2 HRAS
13 12.14 PTPN11 NRAS HRAS ABL1
14 12.06 PTPN11 JAK2 HRAS ABL1
15
Show member pathways
12.03 NRAS JAK2 HRAS
16
Show member pathways
11.99 PTPN11 NRAS NF1 JAK2 HRAS ABL1
17
Show member pathways
11.95 NRAS JAK2 HRAS ABL1
18
Show member pathways
11.91 NRAS NF1 JAK2 HRAS
19 11.83 NRAS JAK2 HRAS
20 11.82 FLT3 CSF3R CSF2
21
Show member pathways
11.81 PTPN11 JAK2 HRAS
22
Show member pathways
11.73 NRAS HRAS FLT3
23
Show member pathways
11.7 PTPN11 JAK2 HRAS
24 11.64 NRAS HRAS FLT3
25 11.61 PTPN11 NRAS NF1 HRAS
26
Show member pathways
11.59 NRAS JAK2 HRAS
27
Show member pathways
11.57 PTPN11 NRAS JAK2 HRAS CSF3R CSF2
28 11.48 PTPN11 HRAS ABL1
29 11.42 NRAS NF1 HRAS
30 11.33 PTPN11 JAK2 HRAS
31 11.1 NF1 HRAS CSF2
32
Show member pathways
10.97 PTPN11 JAK2 HRAS
33 10.75 NRAS HRAS

GO Terms for Myelodysplastic/myeloproliferative Neoplasm

Cellular components related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 U2AF1 TET2 SRSF2 SETBP1 RARS1 PTPN11
2 nucleoplasm GO:0005654 9.44 U2AF1 SRSF2 SETBP1 RARS1 PTPN11 LUC7L2

Biological processes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 chromatin organization GO:0006325 9.65 TET2 KMT2A JAK2 DNMT3A ASXL1
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.63 PTPN11 JAK2 ABL1
3 Ras protein signal transduction GO:0007265 9.58 NRAS NF1 HRAS
4 cytokine-mediated signaling pathway GO:0019221 9.55 PTPN11 JAK2 FLT3 CSF3R CSF2
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 JAK2 FLT3 CSF2
6 negative regulation of cell-cell adhesion GO:0022408 9.49 JAK2 ABL1
7 dendritic cell differentiation GO:0097028 9.48 FLT3 CSF2
8 regulation of myeloid cell differentiation GO:0045637 9.43 CSF3R CSF2
9 Bergmann glial cell differentiation GO:0060020 9.32 PTPN11 ABL1
10 platelet-derived growth factor receptor signaling pathway GO:0048008 9.13 PTPN11 JAK2 ABL1
11 MAPK cascade GO:0000165 9.1 NRAS NF1 JAK2 HRAS FLT3 CSF2

Molecular functions related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 U2AF1 TET2 SRSF2 SETBP1 RARS1 PTPN11
2 insulin receptor substrate binding GO:0043560 9.16 PTPN11 JAK2
3 peptide hormone receptor binding GO:0051428 8.96 PTPN11 JAK2

Sources for Myelodysplastic/myeloproliferative Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....